title: Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas.
abstract: Prognostic relevance of cell proliferation markers was evaluated in 27 glioma patients. By 1) flow cytometry (FCM), i.e., S-phase fraction (SPF), and BrdUrd-labeling index (LIfcm); 2) immunohistochemistry (IHC), i.e., BrdUrd-labeling index (LIihc) and MIB-1 immunoreactivity (MIB-1 LIihc); and 3) histologic examination, i.e., the presence or absence of cells in mitoses, were assessed. A longer local progression free survival (LPFS) was significantly associated with low SPF, low LIfcm, and low MIB-1 LIihc. For LIihc, no significant association was found. LIfcm appeared to be a more promising prognosticator than MIB-1 LIihc. In comparison with this marker, the presence or absence of mitotic figures appeared to be an even stronger prognosticator. Prognostic significance of LIfcm appeared to be of importance in low-grade gliomas. The number of patients in our study is limited. Our findings were: 1) the presence or absence of cells in mitoses (M-phase activity) appeared to be of more prognostic significance than LIfcm (S-phase activity) and MIB-1 LIihc (non-G0-phase activity); 2) of the tested experimental cell proliferation markers, LIfcm appeared to be of more prognostic significance than MIB-1 LIihc, SPF, and LIihc; and 3) LIfcm is likely to be an important prognosticator in low-grade gliomas and is, therefore, not definitive and only of potential interest.
authors.affiliation: Department of Radiotherapy, University Hospital, Utrecht, The Netherlands. h.struikmans@radcl.ruu.nl
authors.forename: H
authors.initials: H
authors.lastname: Struikmans
authors.forename: D H
authors.initials: DH
authors.lastname: Rutgers
authors.forename: G H
authors.initials: GH
authors.lastname: Jansen
authors.forename: H F
authors.initials: HF
authors.lastname: Dullens
authors.forename: L
authors.initials: L
authors.lastname: Oosten
authors.forename: C A
authors.initials: CA
authors.lastname: Tulleken
authors.forename: I
authors.initials: I
authors.lastname: van der Tweel
authors.forename: J J
authors.initials: JJ
authors.lastname: Battermann
mesh_terms: D000328:Adult; D000368:Aged; D034961:Antigens, Nuclear; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D001973:Bromodeoxyuridine / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D005910:Glioma / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D008940:Mitotic Index; D009687:Nuclear Proteins / Q000378:metabolism*; D011379:Prognosis; D012189:Retrospective Studies; D016196:S Phase
chemical_list: D034961:Antigens, Nuclear; D004273:DNA, Neoplasm; D019394:Ki-67 Antigen; D009687:Nuclear Proteins; D001973:Bromodeoxyuridine